Alphatec (NASDAQ:ATEC) Price Target Cut to $12.00 by Analysts at Wells Fargo & Company

Alphatec (NASDAQ:ATEC) had its price objective reduced by analysts at Wells Fargo & Company from $14.00 to $12.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical technology company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 72.84% from the company’s current price.

ATEC has been the topic of several other reports. BMO Capital Markets lowered Alphatec from an “outperform” rating to a “market perform” rating and set a $8.00 target price on the stock. in a research note on Friday. Wall Street Zen downgraded Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, October 11th. UBS Group lifted their price objective on Alphatec from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Alphatec in a research note on Monday, August 3rd. Finally, Stephens assumed coverage on shares of Alphatec in a report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price objective on the stock. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.87.

Alphatec Stock Performance

ATEC stock traded down $4.43 during mid-day trading on Friday, hitting $6.94. The company had a trading volume of 15,370,163 shares, compared to its average volume of 2,967,157. The firm has a market cap of $1.07 billion, a PE ratio of -9.81 and a beta of 0.78. Alphatec has a 12 month low of $6.81 and a 12 month high of $23.29. The stock’s fifty day moving average price is $10.18 and its two-hundred day moving average price is $10.67.

Alphatec (NASDAQ:ATEC) last released its earnings results on Thursday, October 29th. The medical technology company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The company had revenue of $221.17 million for the quarter, compared to the consensus estimate of $225.16 million. During the same period in the prior year, the company earned $0.03 earnings per share. The firm’s revenue was up 12.6% on a year-over-year basis. Equities analysts anticipate that Alphatec will post -0.45 earnings per share for the current year.

Insider Activity

In other news, General Counsel Tyson Marshall sold 8,168 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the completion of the transaction, the general counsel directly owned 630,398 shares in the company, valued at $6,083,340.70. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Patrick Miles purchased 115,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was purchased at an average cost of $8.81 per share, for a total transaction of $1,013,150.00. Following the acquisition, the chief executive officer owned 5,893,551 shares of the company’s stock, valued at approximately $51,922,184.31. This trade represents a 1.99% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 13.48% of the company’s stock.

Institutional Trading of Alphatec

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE grew its holdings in shares of Alphatec by 26.9% during the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock worth $27,863,000 after purchasing an additional 543,059 shares in the last quarter. Emerald Advisers LLC grew its stake in Alphatec by 10.4% in the 1st quarter. Emerald Advisers LLC now owns 1,807,307 shares of the medical technology company’s stock worth $19,664,000 after buying an additional 169,578 shares in the last quarter. Granite Investment Partners LLC grew its stake in Alphatec by 4.7% in the 1st quarter. Granite Investment Partners LLC now owns 1,195,156 shares of the medical technology company’s stock worth $13,003,000 after buying an additional 54,043 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its holdings in shares of Alphatec by 27.1% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 1,156,826 shares of the medical technology company’s stock worth $12,586,000 after buying an additional 246,773 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Alphatec by 21.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,055,100 shares of the medical technology company’s stock valued at $11,479,000 after buying an additional 184,969 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

More Alphatec News

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings improved to $0.09 per share from $0.03 a year earlier. Management also maintained a goal of reaching a 16% adjusted EBITDA margin in 2026. Alphatec Third-Quarter Earnings Results
• Neutral Sentiment: Alphatec reported quarterly EPS of $0.09, which was higher than last year but below analyst expectations of roughly $0.10–$0.11. Revenue also fell short of the approximately $225 million consensus estimate, limiting the positive impact of year-over-year growth. Alphatec Q3 Earnings and Revenue Miss
• Negative Sentiment: The company cut its 2026 revenue forecast to $862 million, below the roughly $882 million FactSet consensus. The revision signals weaker expected growth and is the primary catalyst weighing on investor sentiment. Alphatec Lowers 2026 Revenue Outlook
• Negative Sentiment: Management attributed the outlook reduction in part to a slump in sales of add-on bone-graft products, as fewer surgeons purchased these products for spinal-fusion procedures. Investors are concerned this weakness could slow adoption of Alphatec’s broader surgical platform. Alphatec Bone-Graft Sales Slump
• Negative Sentiment: BMO Capital Markets downgraded ATEC from “outperform” to “market perform” and assigned an $8 price target. Although the target implies some potential upside from recent trading levels, the downgrade reinforces concerns about near-term execution and growth. BMO Downgrades Alphatec

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.